Senior Counsel Scott Penner is quoted in an article in Diagnostic Imaging, “The Radiologist’s Guide to Inventing,” about how best to introduce an invention to the market.
Penner said the technology transfer office (TTO) should be the first stop when pursuing an invention, particularly for those working in an academic environment. In many cases, a university will claim the patent, and inventors may have to give the academic institution the opportunity to have first right of refusal. In some cases, though, universities may give inventors permission to go forward on their own.
Ultimately, he said, the TTO can be an invaluable partner, helping to put inventors in touch with the right resources and to draft an effective business plan.
Penner said the technology transfer office (TTO) should be the first stop when pursuing an invention, particularly for those working in an academic environment. In many cases, a university will claim the patent, and inventors may have to give the academic institution the opportunity to have first right of refusal. In some cases, though, universities may give inventors permission to go forward on their own.
Ultimately, he said, the TTO can be an invaluable partner, helping to put inventors in touch with the right resources and to draft an effective business plan.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”